X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (17) 17
male (16) 16
adult (15) 15
female (14) 14
middle aged (14) 14
aged (13) 13
survival (10) 10
index medicus (9) 9
hematology (8) 8
aged, 80 and over (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6) 6
leukemia, myelogenous, chronic, bcr-abl positive - genetics (6) 6
remission induction (6) 6
therapy (6) 6
adolescent (5) 5
al amyloidosis (5) 5
hemic and lymphatic diseases (5) 5
imatinib mesylate (5) 5
leukemia, myelogenous, chronic, bcr-abl positive - mortality (5) 5
oncology (5) 5
primary systemic amyloidosis (5) 5
protein kinase inhibitors - administration & dosage (5) 5
treatment outcome (5) 5
amyloidosis (4) 4
cardiac & cardiovascular systems (4) 4
chronic myeloid leukemia (4) 4
disease-free survival (4) 4
fusion proteins, bcr-abl - genetics (4) 4
high-dose melphalan (4) 4
nilotinib (4) 4
prognosis (4) 4
pyrimidines - therapeutic use (4) 4
risk factors (4) 4
transplantation (4) 4
amyloidosis - mortality (3) 3
amyloidosis - therapy (3) 3
analysis (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
cancer (3) 3
chronic myeloid-leukemia (3) 3
cytarabine - administration & dosage (3) 3
dasatinib (3) 3
drug administration schedule (3) 3
echocardiography (3) 3
electrocardiography (3) 3
heart transplantation (3) 3
imatinib (3) 3
kaplan-meier estimate (3) 3
leukemia (3) 3
leukemia, myelogenous, chronic, bcr-abl positive - pathology (3) 3
medicine & public health (3) 3
piperazines - therapeutic use (3) 3
prospective studies (3) 3
risk assessment (3) 3
stem cell transplantation (3) 3
stem-cell transplantation (3) 3
surgery (3) 3
survival rate (3) 3
transplantation, autologous (3) 3
young adult (3) 3
3122 cancers (2) 2
abridged index medicus (2) 2
amyloidosis - diagnosis (2) 2
amyloidosis - surgery (2) 2
antimitotic agents (2) 2
antineoplastic agents (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
autologous stem cell transplantation (2) 2
benzamides - administration & dosage (2) 2
benzamides - therapeutic use (2) 2
biomarkers, tumor - genetics (2) 2
blast crisis (2) 2
brain natriuretic peptide (2) 2
cardiomyopathies - diagnosis (2) 2
care and treatment (2) 2
chemotherapy (2) 2
chronic myelogenous leukemia (2) 2
chronic-phase (2) 2
clinical medicine (2) 2
clinical-trials (2) 2
combined modality therapy (2) 2
cytogenetic response (2) 2
diagnosis (2) 2
disease (2) 2
disease progression (2) 2
drug therapy (2) 2
follow-up studies (2) 2
fusion proteins, bcr-abl - antagonists & inhibitors (2) 2
fusion proteins, bcr-abl - metabolism (2) 2
heart (2) 2
heart failure (2) 2
imatinib discontinuation (2) 2
immunoglobulin light chains (2) 2
immunology (2) 2
institut für medizinische informationsverarbeitung, biometrie und epidemiologie (2) 2
interferon-alpha (2) 2
interferon-alpha - administration & dosage (2) 2
involvement (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 02/2014, Volume 32, Issue 5, pp. 415 - 423
Purpose Deep molecular response (MR4.5) defines a subgroup of patients with chronic myeloid leukemia (CML) who may stay in unmaintained remission after... 
MESYLATE | INTERFERON-ALPHA | THERAPY | CHRONIC-PHASE | ONCOLOGY | RECOMMENDATIONS | CLINICAL-TRIALS | 800 MG | END-POINTS | EUROPEAN-LEUKEMIANET | CHRONIC MYELOID-LEUKEMIA | Piperazines - administration & dosage | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Young Adult | Benzamides - administration & dosage | Time Factors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Aged, 80 and over | Adult | Female | Benzamides - adverse effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Pyrimidines - administration & dosage | Risk Factors | Proportional Hazards Models | Treatment Outcome | Imatinib Mesylate | Piperazines - adverse effects | Remission Induction | Cytarabine - administration & dosage | Disease Progression | Interferon-alpha - administration & dosage | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Fusion Proteins, bcr-abl - antagonists & inhibitors | Pyrimidines - adverse effects | Aged | Fusion Proteins, bcr-abl - metabolism
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 747 - 757
Tyrosine kinase inhibitors (TKIs) have improved the survival of patients with chronic myeloid leukaemia. Many patients have deep molecular responses, a... 
SURVIVAL | MAJOR MOLECULAR RESPONSE | TREATMENT-FREE REMISSION | ONCOLOGY | IMATINIB DISCONTINUATION | DISEASE | FOLLOW-UP | DASATINIB | WITHDRAWAL SYNDROME | NILOTINIB | PHASE-2 TRIAL | Predictive Value of Tests | Prospective Studies | Humans | Middle Aged | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Clinical Decision-Making | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Polymerase Chain Reaction | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Drug Administration Schedule | Risk Assessment | Europe | Risk Factors | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | Progression-Free Survival | Fusion Proteins, bcr-abl - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Antimitotic agents | Tyrosine | Antineoplastic agents | Analysis | Life Sciences | Hematology | Human health and pathology | Clinical Medicine | Medical and Health Sciences | Cancer and Oncology | Klinisk medicin | Medicin och hälsovetenskap | Cancer och onkologi
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 26, pp. 3870 - 3879
Journal Article
Annals of Hematology, ISSN 0939-5555, 12/2015, Volume 94, Issue 12, pp. 2015 - 2024
Journal Article
Annals of Hematology, ISSN 0939-5555, 1/2014, Volume 93, Issue 1, pp. 71 - 80
Since the advent of tyrosine kinase inhibitors, the impact of age on outcome of chronic myeloid leukemia (CML) patients has changed. We therefore analyzed... 
Medicine & Public Health | Hematology | Young adults and adolescents | Oncology | Accelerated phase | Blast crisis | Chronic myeloid leukemia | DIAGNOSIS | ADULTS | CANCER | TYROSINE KINASE INHIBITORS | IMPACT | Chronicmyeloid leukemia | THERAPY | ADOLESCENTS | CLINICAL-TRIALS | IMATINIB | HEMATOLOGY | AGE | Piperazines - administration & dosage | Age Factors | Follow-Up Studies | Humans | Middle Aged | Male | RNA, Neoplasm - blood | Young Adult | Benzamides - administration & dosage | Benzamides - therapeutic use | Karnofsky Performance Status | Fusion Proteins, bcr-abl - blood | Splenomegaly - etiology | Adult | Female | Randomized Controlled Trials as Topic - statistics & numerical data | Pyrimidines - administration & dosage | Leukemia, Myeloid, Chronic-Phase - blood | Leukemia, Myeloid, Chronic-Phase - drug therapy | Risk Factors | Kaplan-Meier Estimate | Treatment Outcome | Piperazines - therapeutic use | Imatinib Mesylate | Cytarabine - administration & dosage | Interferon-alpha - administration & dosage | Leukemia, Myeloid, Chronic-Phase - mortality | Protein Kinase Inhibitors - administration & dosage | Fusion Proteins, bcr-abl - genetics | RNA, Messenger - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Adolescent | Aged | Leukemia, Myeloid, Chronic-Phase - genetics | Hemoglobin | Research | Analysis | Oncology, Experimental | Cancer | Original
Journal Article
Blood, ISSN 0006-4971, 11/2019, Volume 134, Issue Supplement_1, pp. 1647 - 1647
Introduction: The single nucleotide polymorphism (SNP) rs460089 (G/C) located in the promotor of SLC22A4 (transporter hOCTN1) was identified as a prognostic... 
Journal Article
Haematologica, ISSN 0390-6078, 09/2014, Volume 99, Issue 9, pp. 1441 - 1447
Journal Article
British Journal of Haematology, ISSN 0007-1048, 12/2004, Volume 127, Issue 5, pp. 543 - 551
Summary Amyloid light chain (AL) amyloidosis is the result of a clonal plasma cell expansion, in which monoclonal light chains transform to amyloid deposit in... 
light chain amyloidosis | vincristine | adriamycin and dexamethasone (VAD) | autologous stem cell transplantation | high-dose melphalan | high‐dose melphalan | High-dose melphalan | Vincristine | Autologous stem cell transplantation | Light chain amyloidosis | Adriamycin and dexamethasone (VAD) | SURVIVAL | DEXAMETHASONE | PRIMARY SYSTEMIC AMYLOIDOSIS | RANDOMIZED-TRIAL | PERIPHERAL-BLOOD | PREDNISONE | THERAPY | COLCHICINE | AL AMYLOIDOSIS | NEPHROTIC SYNDROME | HEMATOLOGY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Humans | Middle Aged | Immunoglobulin kappa-Chains | Male | Transplantation, Autologous | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Melphalan - therapeutic use | Stem Cell Transplantation | Vincristine - administration & dosage | Adult | Female | Immunoglobulin lambda-Chains | Hematopoietic Stem Cell Mobilization | Doxorubicin - administration & dosage | Amyloidosis - therapy | Dexamethasone - administration & dosage | Drug Administration Schedule | Amyloidosis - mortality | Survival Rate | Combined Modality Therapy | Remission Induction | Immunoglobulin Light Chains | Regression Analysis | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged
Journal Article
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 1891 - 1891
Abstract Background: ENESTop (NCT01698905) is an ongoing, single-arm, phase 2 study evaluating treatment-free remission (TFR) in patients (pts) with chronic... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 792 - 792
Abstract Background: ENESTop, an ongoing, single-arm, phase 2 study (ClinicalTrials.gov, NCT01698905), is the first trial specifically evaluating... 
Journal Article
Journal Article